Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

181. Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression

Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression Biondi-Zoccai G G, Lotrionte M, Agostoni P, Valgimigli M, Abbate A, Sangiorgi G, Moretti C (...) , Sheiban I CRD summary This review concluded that clopidogrel given with an initial loading dose is associated with a reduced risk of death or heart attack compared with ticlopidine in patients undergoing coronary stenting. The review had methodological limitations and relied mainly on short-term studies with small numbers of events, hence the conclusions should be treated with caution. Authors' objectives To assess the effectiveness of clopidogrel versus ticlopidine in patients undergoing coronary

2007 DARE.

182. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials

Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials Berg H, Lindgren P, Spiesser J, Parry D, Jonsson B Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated two treatment options for patients with ST-segment elevation myocardial infarction (STEMI). The options were clopidogrel in combination with acetylsalicylic acid (ASA) and ASA alone. Type

2007 NHS Economic Evaluation Database.

183. Clopidogrel after drug-eluting stent implantation

Clopidogrel after drug-eluting stent implantation Clopidogrel after drug-eluting stent implantation | Therapeutics Initiative Independent Healthcare Evidence > > Clopidogrel after drug-eluting stent implantation Background information of the condition: Drug Eluting Stents (DES) Implantation DES were invented to reduce restenosis compared to bare metal stents (8% vs. 25% , respectively). The process responsible for stent stenosis is delayed with drugs (sirolimus [rapamycin] and paclitaxel (...) ); however this benefit is offset by harm due to stent thrombosis (0.2-1.1%). Dual antiplatelet therapy is recommended to decrease the rate of stent thrombosis. Drug (Product Monograph ) Category Clopidogrel is categorized as platelet aggregation inhibitor. Mechanism of action : Clopidogrel selectively inhibits the binding of ADP to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein IIb-IIIa complex, thereby inhibiting platelet aggregation. Indication : Clopidogrel

2007 Therapeutics Letter

184. Prasugrel versus clopidogrel in patients with acute coronary syndromes. Full Text available with Trip Pro

Prasugrel versus clopidogrel in patients with acute coronary syndromes. Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention.To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg (...) loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding.The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence

2007 NEJM Controlled trial quality: predicted high

185. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention

Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention Heeg B M, Peters R J, Botteman M, van Hout B A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the use of short-term versus long-term therapy with clopidogrel, in patients undergoing percutaneous coronary intervention, either electively or as patients with acute coronary syndrome. The authors concluded that long-term clopidogrel resulted in cost savings and increased the number of life-years and QALYs gained compared with short-term clopidogrel treatment

2007 NHS Economic Evaluation Database.

186. Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial

Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial Kolm P, Yuan Y, Veledar E, Mehta S R, O'Brien J A, Weintraub W S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the long-term cost-effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone. The authors concluded that clopidogrel plus ASA therapy was cost-effective compared with ASA alone. Overall the methodology was good

2007 NHS Economic Evaluation Database.

187. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany

Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany Bruggenjurgen B, Lindgren P, Ehlken B, Rupprecht H J, Willich S N Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined 1-year of clopidogrel added to acetylsalicylic acid (ASA) in patients with acute coronary syndrome without ST-segment elevation. Clopidogrel plus ASA was compared with ASA monotherapy. Type of intervention Secondary prevention

2007 NHS Economic Evaluation Database.

188. Should clopidogrel be stopped prior to urgent cardiac surgery?

Should clopidogrel be stopped prior to urgent cardiac surgery? BestBets: Should clopidogrel be stopped prior to urgent cardiac surgery? Should clopidogrel be stopped prior to urgent cardiac surgery? Report By: Babu Kunadian, Andrew R. Thornley, Marios Tanos - Cardiothoracic Registrars Search checked by Joel Dunning - Cardiothoracic Registrar RCS Institution: Department of Cardiothoracic Surgery, James Cook University Hospital and Freeman Hospital, Newcastle-upon-Tyne Date Submitted: 18th (...) September 2006 Date Completed: 26th October 2006 Last Modified: 18th September 2006 Status: Green (complete) Three Part Question In patients undergoing [urgent Coronary Arterial Bypass grafting] can surgery [with recent clopidogrel administration] be safely performed [early without excessive bleeding] Clinical Scenario You have been asked to perform urgent CABG on a 72 year old gentleman who has just undergone angiography for acute coronary syndrome. He had been admitted that day with chest pain at rest

2007 BestBETS

189. Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Full Text available with Trip Pro

Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Article Text Therapeutics Aspirin plus esomeprazole reduced recurrent ulcer bleeding

2006 Evidence-Based Medicine

190. Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy Full Text available with Trip Pro

Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy Article Text Therapeutics

2006 Evidence-Based Medicine

191. Clopidogrel plus aspirin or aspirin alone in unstable angina

Clopidogrel plus aspirin or aspirin alone in unstable angina BestBets: Clopidogrel plus aspirin or aspirin alone in unstable angina Clopidogrel plus aspirin or aspirin alone in unstable angina Report By: Shweta Gidwani - Clinical Effectiveness Fellow Search checked by Richard Body - Clinical Research Fellow Institution: Manchester Royal Infirmary Original author: Shweta Gidwani Original institution: Manchester Royal Infirmary Date Submitted: 25th November 2005 Date Completed: 2nd February 2006 (...) Last Modified: 1st December 2005 Status: Green (complete) Three Part Question In [patients suspected to have unstable angina] is [the use of clopidogrel plus asprin better than asprin alone] at [improving cardiovascular outcome] Clinical Scenario A 55 year old man, known to have angina, presents to the Emergency Department with new-onset typical ischaemic rest pain that is not relieved by his nitrate spray at home. His ECG shows ST depression in V3-V6. He is haemodynamically stable. You treat him

2006 BestBETS

192. Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases

Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases 1 - Final report - [Commission No. A04-01A] 1 Publication date of the English translation: 04 October 2006. This translation is based on the German final report “Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen” (Version 1.0, 30 June 2006). Please note: The translation (...) is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Final report A04-01A: Clopidogrel versus ASA for secondary prevention of vascular diseases 2 Topic: Evaluation of the benefits and harms of clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases Contracting agency: Federal Joint Committee (Gemeinsamer Bundesausschuss) Date of Commission: 15 December 2004 Internal

2006 Institute for Quality and Efficiency in Healthcare (IQWiG)

193. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. Full Text available with Trip Pro

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events.We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed (...) them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes.The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspirin and 7.3 percent with placebo plus aspirin (relative risk, 0.93; 95 percent confidence interval, 0.83 to 1.05; P=0.22). The respective rate of the principal secondary efficacy end point, which included hospitalizations for ischemic events, was 16.7 percent and 17.9

2006 NEJM Controlled trial quality: predicted high

194. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. Full Text available with Trip Pro

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. No specifically designed studies have addressed the role of the glycoprotein IIb/IIIa inhibitor abciximab in patients with non-ST-segment elevation acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with 600 mg of clopidogrel.To assess whether abciximab is associated with clinical (...) heparin, 70 U/kg of body weight) or placebo (placebo bolus and infusion of 12 hours, plus heparin bolus, 140 U/kg). All patients received clopidogrel, 600 mg, at least 2 hours prior to the procedure, as well as 500 mg of oral or intravenous aspirin.The primary end point was a composite of death, myocardial infarction, or urgent target vessel revascularization occurring within 30 days after randomization; secondary end points were rates of in-hospital major and minor bleeding.Of 2022 patients enrolled

2006 JAMA Controlled trial quality: predicted high

195. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. (Abstract)

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Oral anticoagulation therapy reduces risk of vascular events in patients with atrial fibrillation. However, long-term monitoring is necessary and many patients cannot achieve optimum anticoagulation. We assessed whether clopidogrel plus aspirin was non-inferior to oral (...) anticoagulation therapy for prevention of vascular events.Patients were enrolled if they had atrial fibrillation plus one or more risk factor for stroke, and were randomly allocated to receive oral anticoagulation therapy (target international normalised ratio of 2.0-3.0; n=3371) or clopidogrel (75 mg per day) plus aspirin (75-100 mg per day recommended; n=3335). Outcome events were adjudicated by a blinded committee. Primary outcome was first occurrence of stroke, non-CNS systemic embolus, myocardial

2006 Lancet Controlled trial quality: predicted high

196. Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases

Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases. Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). 2006 Authors' objectives The aims of this evaluation were: 1. the comparative evaluation of the benefits and harms of clopidogrel and ASA as antiplatelet monotherapy for secondary prevention in patients

2006 Health Technology Assessment (HTA) Database.

197. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK

A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, Gray D, Akehurst R Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined 1-year of treatment with 75 mg/day clopidogrel (with a 300-mg loading dose), an adenosine diphosphate receptor antagonist, in the treatment of non-ST-segment-elevation acute coronary syndrome (ACS). Type of intervention Secondary

2006 NHS Economic Evaluation Database.

198. Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation

Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Article Text Therapeutics Clopidogrel plus aspirin

2006 Evidence-Based Medicine

199. Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Article Text

2006 Evidence-Based Medicine

200. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. (Abstract)

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Although clopidogrel plus aspirin is more effective than aspirin alone in preventing subsequent vascular events in patients with unstable angina, the cost-effectiveness of this combination has yet to be examined in this high-risk population.To determine the cost-effectiveness of clopidogrel plus aspirin compared with aspirin alone.Cost-utility (...) analysis.Published literature.Patients with unstable angina and electrocardiographic changes or non-Q-wave myocardial infarction. time horizon: Lifetime.Societal.Combination therapy with clopidogrel, 75 mg/d, plus aspirin, 325 mg/d, for 1 year, followed by aspirin monotherapy, was compared with lifelong aspirin therapy, 325 mg/d.Lifetime costs, life expectancy in quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio.Patients treated with aspirin alone lived 9.51 QALYs after

2005 Annals of Internal Medicine